Posted by Michael Wonder on 22 Jul 2026
Marketing authorisation application for in-house developed insomnia drug lemborexant accepted for evaluation by EMA
16 July 2026 - Eisai announced today that the EMA has accepted for evaluation a marketing authorization application for its in-house discovered and developed orexin receptor antagonist lemborexant for the treatment of adult patients with chronic insomnia.
Lemborexant is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep and wake states by binding competitively to the two subtypes of orexin receptors.
